Eli Lilly and Company, Moderna, Johnson & Johnson, UnitedHealth Group, Natera, AbbVie, and Thermo Fisher Scientific are the seven Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are shares of publicly traded companies involved in healthcare, such as pharmaceutical and biotech firms, medical-device makers, hospitals, and health insurers. Investors buy them to gain exposure to the healthcare sector, whose performance can be influenced by medical innovation, regulation, and demand for care. These companies had the highest dollar trading volume of any Healthcare stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
LLY stock traded up $7.42 during midday trading on Friday, hitting $1,372.15. The company's stock had a trading volume of 3,802,992 shares, compared to its average volume of 2,816,128. The company's fifty day moving average price is $1,215.24 and its 200 day moving average price is $1,101.16. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,453.00. The stock has a market capitalization of $1.29 trillion, a P/E ratio of 44.54, a PEG ratio of 1.69 and a beta of 0.40.
Read Our Latest Research Report on LLY
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Shares of Moderna stock traded up $12.73 during trading hours on Friday, reaching $254.19. 16,295,043 shares of the company's stock were exchanged, compared to its average volume of 17,257,506. The company has a 50 day moving average of $191.85 and a two-hundred day moving average of $91.51. Moderna has a fifty-two week low of $22.28 and a fifty-two week high of $267.50. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The stock has a market cap of $101.48 billion, a P/E ratio of -35.80 and a beta of 1.16.
Read Our Latest Research Report on MRNA
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Shares of NYSE:JNJ traded up $3.82 during midday trading on Friday, reaching $276.14. The company had a trading volume of 8,859,790 shares, compared to its average volume of 7,963,982. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The business's 50 day moving average price is $265.91 and its 200 day moving average price is $248.30. The stock has a market cap of $664.76 billion, a PE ratio of 41.84, a P/E/G ratio of 2.73 and a beta of 0.22. Johnson & Johnson has a 1-year low of $185.12 and a 1-year high of $282.02.
Read Our Latest Research Report on JNJ
UnitedHealth Group (UNH)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.
NYSE UNH traded down $1.57 during trading hours on Friday, hitting $394.14. 5,901,850 shares of the company traded hands, compared to its average volume of 6,195,700. The business's 50-day moving average is $390.62 and its 200-day moving average is $364.03. UnitedHealth Group has a twelve month low of $255.96 and a twelve month high of $461.62. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 0.74. The stock has a market capitalization of $353.16 billion, a price-to-earnings ratio of 22.51, a P/E/G ratio of 1.43 and a beta of 0.51.
Read Our Latest Research Report on UNH
Natera (NTRA)
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Shares of NASDAQ:NTRA traded down $53.09 during trading on Friday, hitting $310.67. 5,775,619 shares of the company were exchanged, compared to its average volume of 1,711,005. The stock has a market cap of $44.78 billion, a price-to-earnings ratio of -272.52 and a beta of 1.55. Natera has a fifty-two week low of $181.00 and a fifty-two week high of $437.41. The firm has a fifty day moving average price of $380.25 and a two-hundred day moving average price of $269.68.
Read Our Latest Research Report on NTRA
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of AbbVie stock traded up $3.27 on Friday, reaching $291.51. 5,039,501 shares of the company were exchanged, compared to its average volume of 5,631,433. AbbVie has a one year low of $190.75 and a one year high of $302.93. The company has a market capitalization of $515.27 billion, a price-to-earnings ratio of 50.17, a PEG ratio of 1.32 and a beta of 0.20. The company has a 50-day moving average of $271.98 and a 200 day moving average of $239.04.
Read Our Latest Research Report on ABBV
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Shares of NYSE:TMO traded up $17.99 during midday trading on Friday, hitting $694.93. The stock had a trading volume of 2,090,723 shares, compared to its average volume of 2,361,969. Thermo Fisher Scientific has a 12 month low of $435.27 and a 12 month high of $712.17. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.71. The business's 50-day simple moving average is $661.03 and its 200-day simple moving average is $554.78. The company has a market cap of $257.48 billion, a P/E ratio of 36.65, a PEG ratio of 2.83 and a beta of 0.84.
Read Our Latest Research Report on TMO
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
